Back to Search
Start Over
The Evolving Role of Immunotherapy in Stage III Non-Small Cell Lung Cancer.
- Source :
-
Current oncology (Toronto, Ont.) [Curr Oncol] 2021 Dec 16; Vol. 28 (6), pp. 5408-5421. Date of Electronic Publication: 2021 Dec 16. - Publication Year :
- 2021
-
Abstract
- The management of Stage III non-small cell lung cancer (NSCLC) is complex and requires multidisciplinary input. Since the publication of the PACIFIC trial (consolidative durvalumab post concurrent chemotherapy and radiation in Stage III disease) which showed improved survival for patients in the immunotherapy arm, there has been much interest in the use of immunotherapy in the Stage III setting. In this review, we explore the biologic and clinical rationale for the use of immunotherapy in Stage III NSCLC, present previously published and upcoming data in the neoadjuvant, adjuvant, and concurrent realms of Stage III management, and discuss unanswered questions and challenges moving forward.
Details
- Language :
- English
- ISSN :
- 1718-7729
- Volume :
- 28
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Current oncology (Toronto, Ont.)
- Publication Type :
- Academic Journal
- Accession number :
- 34940090
- Full Text :
- https://doi.org/10.3390/curroncol28060451